Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

'Report Predicts Generic Drug Revenues Will Reach $137.6bn in 2015' Says Visiongain Analyst


News provided by

Visiongain Ltd

14 Sep, 2011, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, September 14, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/681/Generic-Drugs-World-Market-Outlook-2011-2021

A new report by visiongain, a London-based business information company, predicts that world generic drug revenues will reach $137.6bn in 2015. That finding appears in Generic Drugs: World Market Outlook 2011-2021, published in September 2011.

The world prescription generics market - worth less than $50bn in 2004 - reached $96.4bn in 2010. If a more-general definition of generic medicines is used, the market may be worth over $150bn a year. In the US, generic drug sales have more than tripled since 2000. Generic drugs now account for about 70% of the prescriptions dispensed in the US. Generic market shares will increase this decade as more branded drugs face patent expiry, most notably blockbusters such as Lipitor.

Visiongain's senior pharma industry analyst, said: "Analysts estimate that branded pharmaceutical manufacturers may lose a potential $50bn in sales due to patent expiries in 2011 alone. This situation means a significant opportunity for generic producers over the next ten years. Expansion of the generics market will continue steadily as legislative demands to control healthcare costs increase, especially in US and European markets."

Other significant growth drivers for the generics industry include a trend for innovator pharmaceutical companies to establish a presence in generics. Companies such as Pfizer and Novartis have built partnerships there and bought generics operations. Generic manufacturing companies have also been active in mergers and acquisitions, seeking to increase scale, revenue, market reach and competitive advantage.

Visiongain forecasts that the world generic drugs market will grow steadily to 2021. This trend is stimulated by increasing life expectancy worldwide, budgetary constraints and developing countries needing affordable medicines, the report concludes. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry areas.  

To see sample pages of the report please click on:

http://www.visiongain.com/Report/681/Generic-Drugs-World-Market-Outlook-2011-2021

Table of Contents
Executive Summary
1.1 Generic Drugs: Industry and Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to the World Generics Market
2.1 Generic Drugs (Generics)
2.1.1 Authorised, Branded and True Generics
2.2 The 'Evergreening' of Pharmaceuticals
2.3 Restraints Facing the World Pharmaceutical Market
2.4 Branded Pharmaceuticals: End of a Business Model?
2.5 US Regulations
2.5.1 Obtaining FDA Approval: NDAs and ANDAs
2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs
2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry
2.5.4 Consequences of the Hatch-Waxman Act
2.5.5 Me First: Timing as a Crucial Factor
2.6 European Regulations
2.6.1 Generics' Entry into the European Markets
2.6.2 Further Protection of Branded Products in the European Market
2.6.3 Variations among European Countries
2.6.4 Moving Towards Standardisation
2.6.5 The 8+2+1 Rule
2.7 Japanese Regulations
2.8 Compulsory Licensing
2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2011-2021
3.1 The World Generic Pharmaceuticals Market in 2010
3.2 Generic Products to Benefit from Patent Expiries
3.2.1 Sales Forecast for the World Generic Drugs Market, 2011-2015
3.2.2 Sales Forecast for the World Generic Drugs Market, 2016-2021
3.3 Global Market Breakdown, 2011-2021

4. Leading Companies in the World Generics Market
4.1 Teva Pharmaceutical Industries - Prospects from 2011
4.1.1 ANDAs and Approvals
4.1.2 M&A Activity
4.2 Sandoz - Prospects from 2011
4.3 Mylan - Prospects from 2011
4.3.1 Mylan's Acquisition of Bioniche Pharma Holdings
4.4 Apotex - Prospects from 2011
4.5 Hospira - Prospects from 2011
4.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business
4.5.2 Hospira's Acquisition of Javelin Pharma
4.6 Watson - Prospects from 2011
4.6.1 ANDAs and Approvals
4.6.2 M&A Activity
4.6.3 Eden Becomes Wholly-Owned Subsidiary of Watson
4.6.4 Watson Acquires Specifar Pharmaceuticals

5. The US Generics Market 2011-2021
5.1 Analysis of the Current Market
5.2 The US Generics Market: Revenue Forecast 2011-2021
5.3 Regulatory Reform Can Keep the Market Growing
5.3.1 A New Pathway to the US Market for Biosimilars?
5.3.2 Reverse Payments
5.3.3 The ANDA Backlog
5.4 Growing Consumer Acceptance of Generic Medicines
5.5 Leading Companies in the US Generics Market
5.6 Concluding Remarks

6. Leading European Generics Markets 2011-2021
6.1 Analysis of the Current Generics Market in Europe
6.2 Revenue Prospects for European Generics Markets 2011-2021
6.2.1 The Two Categories of European Market
6.2.2 European Pricing Systems and their Effect on Generic Penetration
6.2.3 Patient Co-Payment
6.2.4 Challenges with the European Regulatory Environment
6.3 The German Generics Market
6.3.1 German Generics Market: Sales Forecast 2011-2021
6.3.2 The Future of the German Generics Market
6.4 The French Generics Market
6.4.1 French Generics Market: Sales Forecast 2011-2021
6.4.2 The Future of the French Generics Market
6.5 The UK Generics Market
6.5.1 UK Generics Market: Sales Forecast 2011-2021
6.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints
6.5.3 Reducing Generic Drug Prices: the Drug Tariff System
6.5.4 The Increasing Role of Pharmacists
6.5.5 Easy Entry, Strong Price Competition
6.5.6 The Future of the UK Generics Market
6.6 The Italian Generics Market
6.6.1 Italian Generics Market: Sales Forecast 2011-2021
6.6.2 Promoting Generic Penetration
6.6.3 Prospects for the Italian Generics Market
6.7 The Spanish Generics Market
6.7.1 Spanish Generics Market: Sales Forecast 2011-2021
6.7.2 Challenges for the Spanish Market
6.7.3 Prospects for the Spanish Generics Market
6.8 Concluding Remarks

7. The Japanese Generics Market 2011-2021
7.1 Analysis of the Current Market
7.2 Japanese Generics Market: Sales Forecast 2011-2021
7.3 Government Initiatives Have Driven Market Growth
7.3.1 Mergers and Acquisitions
7.4 Concluding Remarks

8. Emerging Generics Markets 2011-2021
8.1 The EM-7: Pharma's Best Hope
8.2 M&A as a Tactic for Entering the Generic Drugs Sector
8.3 Turkish Generics Market: Sales Forecast 2011-2021
8.4 Brazilian Generics Market: Sales Forecast 2011-2021
8.5 Mexican Generics Market: Sales Forecast 2011-2021
8.6 South Korean Generics Market: Sales Forecast 2011-2021
8.7 Russian Federation Generics Market: Sales Forecast 2011-2021
8.7.1 Russian Federation Generics Market, 2011-2021
8.7.2 Analysis of the Russian Federation Market
8.8 India - Market Prospects from 2011
8.8.1 Indian Generics Market: Sales Forecast 2011-2021
8.8.2 International Success of India's Pharmaceutical Industry
8.9 China - Market Prospects from 2011
8.9.1 Chinese Generics Market: Sales Forecast 2011-2021
8.9.2 Chinese Generics Market: Discussion of Sector

9. World Generics Market: Strengths, Weaknesses, Opportunities and Threats
9.1 The Generics Sector Will Remain a High-Growth Area
9.2 Generics Offer Limited Profitability
9.3 Emerging Markets and Generics: The Pharma Industry's Biggest Opportunity?
9.4 The Generic Drug Market's Growth is Assured, but Some Threats Remain

10. Opinions from Our Survey - Research Interviews
10.1 James Harris, CEO, Healthcare Economics LLC, Florida, USA
10.1.1 Main Challenges for the US Generics Market
10.1.2 Pricing Trends in Generic Products
10.1.3 On Authorised Generic Products
10.1.4 Current State of Biogeneric (Biosimilar) Legislation in the US
10.1.5 On Para 4 Challenges and Patent Cliff
10.1.6 On Generics Market in the Next Decade
10.2 Charlie Mayr, Generic Pharmaceutical Association (GPhA)
10.2.1 The Value of the Generics Market
10.2.2 Main Challenges for the US Generics Market
10.2.3 On Growth Trend in Generic Products
10.2.4 On US Pricing Trends in Generic Products
10.2.5 On Authorised Generic Products
10.2.6 On Biogeneric (Biosimilar) Products

11. Conclusions
11.1 The World Generics Market Will Continue to Expand
11.2 The Emerging National Markets Hold Much Promise
11.3 Biosimilars Have Promise, but Difficulties and Uncertainties Remain
11.4 Concluding Remarks

Appendices
Appendix A: Supplementary Information: Patent Expiries
Appendix B: About Visiongain
Appendix C: Visiongain Report Evaluation Form


Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an exec summary please contact Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207336-6100
Web: http://www.visiongain.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.